Lyrica

ApprovedSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lyrica is one of 281 small molecule programs targeting Neuropathic Pain. It is currently in Approved.

Indications

Total Trials

Active Trials

280

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

Peripheral NeuropathyActive, not recruiting

MucositisActive, not recruiting

Total Knee ArthroplastyActive, not recruiting

SeizureActive, not recruiting

Postherpetic NeuralgiaActive, not recruiting

EpilepsyActive, not recruiting

FibromyalgiaActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Neuropathic PainPhase 3

Active, not recruiting

Peripheral NeuropathyPhase 3

Active, not recruiting

MucositisPreclinical

Active, not recruiting

Total Knee ArthroplastyApproved

Active, not recruiting

SeizureApproved

Active, not recruiting

Postherpetic NeuralgiaApproved

Active, not recruiting

EpilepsyPreclinical

Active, not recruiting

FibromyalgiaPhase 2

Active, not recruiting

Spinal Cord InjuryPhase 3

Active, not recruiting

Competition

Competitive Landscape

275 competitors in Total Knee Arthroplasty

#DrugCompanyPhaseTrials

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

5 3

Xarelto

WWim Janssens

Preclinical

5 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 5

Sufenta

LLeaf Vertical Inc.

Preclinical

3 6

EXPAREL

Pacira Pharmaceuticals, Inc

Preclinical

7 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

2 8

Nucynta

CCollegium Pharmaceutical, Inc.

Preclinical

2 9

Zanaflex

LLegacy Health System

Preclinical

1 10

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuropathic Pain2 trials

Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain

Unknown status·KKunWha Pharmaceutical Co., Ltd.·Phase 3·NCT01863810·394 enrolled

Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

Completed·YYuhan Corporation·Phase 3·NCT02985216·371 enrolled

Pregabalin2 trials

Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects

Completed· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 1·NCT02103686·30 enrolled

PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers

Completed·YYuhan Corporation·Phase 1·NCT02783638·64 enrolled

Spinal Cord Injury1 trial

Study of Pregabalin in the Prevention of Central Neuropathic Pain in Acute Spinal Cord Injury

Terminated·NNova Scotia Health Authority·Phase 3·NCT00879021·5 enrolled

Randomized1 trial

A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin

Completed·YYuhan Corporation·Phase 1·NCT02783183·32 enrolled

Peripheral Neuropathy1 trial

Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy

Withdrawn·EEurofarma Laboratorios S.A.·Phase 3·NCT06715462

9 more indications

Mastectomy1 trial

Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica

Completed·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT01391858·80 enrolled

Total Knee Arthroplasty1 trial

Pre vs Post Block in Total Knee Arthroplasty (TKA)

Completed·UUniversity of Miami·Phase 4·NCT05974501·84 enrolled

Ankle Surgery1 trial

Opiate Free Multimodal Pain Pathway in Elective Foot and Ankle Surgery: A Prospective Study

Completed·PPrisma Health-Midlands··NCT04771741·72 enrolled

Fibromyalgia1 trial

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00696787·125 enrolled

Seizure1 trial

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00351611·187 enrolled

Mucositis1 trial

A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.

Completed·—·N/A·NCT02277548·20 enrolled

Completed·YYungjin Pharm. Co., Ltd.·Phase 1·NCT03261427·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Lyrica. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lyrica compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lyrica. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lyrica

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuropathic Pain2 trials

Pregabalin2 trials

Spinal Cord Injury1 trial

Randomized1 trial

Peripheral Neuropathy1 trial

Mastectomy1 trial

Total Knee Arthroplasty1 trial

Ankle Surgery1 trial

Fibromyalgia1 trial

Seizure1 trial

Mucositis1 trial

Epilepsy1 trial

Postherpetic Neuralgia1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News